See more : Canada Goose Holdings Inc. (GOOS) Income Statement Analysis – Financial Results
Complete financial analysis of Generex Biotechnology Corporation (GNBTQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Generex Biotechnology Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Atrium European Real Estate Ltd (ATRS.AS) Income Statement Analysis – Financial Results
- Action Construction Equipment Limited (ACE.NS) Income Statement Analysis – Financial Results
- Griñó Ecologic, S.A. (GRI.MC) Income Statement Analysis – Financial Results
- G Squared Ascend I Inc. (GSQD) Income Statement Analysis – Financial Results
- Shanghai Construction Group Co., Ltd. (600170.SS) Income Statement Analysis – Financial Results
Generex Biotechnology Corporation (GNBTQ)
About Generex Biotechnology Corporation
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.66M | 6.20M | 703.24K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.65K | 291.63K | 1.17M | 1.12M | 124.89K | 180.20K | 175.00K | 392.11K | 627.18K | 0.00 | 0.00 | 1.00M | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 579.86K | 4.14M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.11K | 155.62K | 812.27K | 527.73K | 52.03K | 61.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -86.81K | -79.78K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.08M | 2.07M | 703.24K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.54K | 136.01K | 360.35K | 590.78K | 72.87K | 118.58K | 175.00K | 392.11K | 627.18K | 0.00 | 0.00 | 1.00M | 86.81K | 79.79K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 78.21% | 33.29% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 61.23% | 46.64% | 30.73% | 52.82% | 58.34% | 65.80% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 8,680,900.00% | 7,978,500.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.11M | 1.75M | 839.15K | 422.29K | 467.38K | 1.19M | 1.38M | 2.19M | 4.99M | 10.25M | 13.36M | 13.56M | 16.36M | 11.98M | 6.19M | 7.75M | 8.52M | 5.15M | 6.62M | 19.15M | 3.48M | 1.85M | 876.40K | 730.00K | 70.00K |
| General & Administrative | 17.90M | 21.41M | 2.36M | 1.17M | 1.44M | 2.70M | 3.02M | 3.94M | 4.89M | 13.39M | 12.72M | 11.16M | 15.60B | 12.32B | 12.69B | 11.20B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 630.00K | 300.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 165.18K | 1.03M | 3.71M | 2.12M | 1.56B | 693.31M | -12.68B | -11.19B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.90M | 21.41M | 2.36M | 1.17M | 1.44M | 2.70M | 3.02M | 3.94M | 5.05M | 14.42M | 16.43M | 13.29M | 17.16M | 13.01M | 12.69M | 11.20M | 10.67M | 8.70M | 7.91M | 13.29M | 5.57M | 4.37M | 3.72M | 630.00K | 300.00K |
| Other Expenses | -184.65K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.81K | 79.78K | 0.00 | 0.00 | -10.00K |
| Operating Expenses | 19.82M | 23.16M | 3.20M | 1.60M | 1.90M | 3.88M | 4.40M | 6.13M | 10.04M | 24.67M | 29.79M | 26.85M | 33.52M | 24.99M | 18.88M | 18.95M | 19.19M | 13.85M | 14.53M | 32.44M | 9.13M | 6.31M | 4.60M | 1.36M | 360.00K |
| Cost & Expenses | 20.40M | 27.30M | 3.20M | 1.60M | 1.90M | 3.88M | 4.40M | 6.13M | 10.05M | 24.82M | 30.60M | 27.37M | 33.57M | 25.06M | 18.88M | 18.95M | 19.19M | 13.85M | 14.53M | 32.44M | 9.04M | 6.23M | 4.60M | 1.36M | 360.00K |
| Interest Income | 0.00 | 47.96K | 0.00 | 0.00 | 0.00 | 6.00 | 586.00 | 353.00 | 1.52K | 6.46K | 27.05K | 237.98K | 1.17B | 2.18B | 767.60M | 22.87M | 249.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 7.10M | 7.09M | 583.59K | 743.10K | 418.50K | 350.03K | 321.67K | 530.22K | 592.53K | 208.91K | 210.08K | 20.11M | -4.28B | -849.55M | -37.59B | -4.30B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.00M | 426.44K | 23.78K | 5.05K | 265.21K | 380.68K | 368.45K | 463.72K | 612.66K | 742.96K | 780.25K | 805.81K | 4.77M | 1.77M | 17.09M | 5.09M | 1.01M | 589.84K | 431.55K | 230.60K | 86.81K | 79.78K | 31.10K | 10.00K | 0.00 |
| EBITDA | -25.23M | -1.83M | 36.94M | -69.27M | -2.54M | -1.46M | 688.70K | -7.56M | -8.29M | -20.72M | -24.29M | -24.89M | -31.46M | -21.73M | -50.87M | -18.91M | -17.35M | -12.67M | -13.26M | -26.87M | -8.75M | -6.16M | -4.63M | -1.35M | -360.00K |
| EBITDA Ratio | -947.91% | -29.46% | 5,253.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,917.30% | -7,106.31% | -2,071.41% | -2,225.45% | -25,186.23% | -12,059.03% | -29,070.00% | -4,823.84% | -2,766.02% | 0.00% | 0.00% | -2,686.66% | -875,423,900.00% | -615,981,800.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.94M | -24.35M | -2.50M | -1.60M | -1.90M | -3.88M | -4.40M | -6.13M | -10.02M | -24.53M | -29.43M | -26.26M | -33.45M | -24.88M | -18.71M | -18.56M | -18.57M | -13.85M | -14.53M | -31.44M | -9.04M | -6.23M | -4.60M | -1.36M | -360.00K |
| Operating Income Ratio | -673.98% | -392.43% | -354.87% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -34,986.73% | -8,412.46% | -2,509.77% | -2,347.43% | -26,779.73% | -13,804.87% | -10,689.13% | -4,732.94% | -2,960.11% | 0.00% | 0.00% | -3,143.75% | -904,395,500.00% | -622,763,000.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -16.31M | 21.08B | 38.44M | -75.24M | -1.32M | 1.69M | -321.67K | -2.42M | 533.77M | -21.65B | -25.25B | -19.56M | -36.20B | -23.48B | -67.95B | -23.98B | 69.97K | 115.17K | 16.00K | 10.66K | 7.91K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -34.23M | -11.01M | 35.95M | -76.83M | -3.22M | -2.19M | -1.42K | -8.55M | -9.49B | -21.68B | -25.28B | -45.81M | -36.23B | -23.50B | -67.97B | -24.00B | -18.50M | -13.73M | -14.51M | -31.43M | -9.04M | 0.00 | 0.00 | -1.36M | -360.00K |
| Income Before Tax Ratio | -1,286.25% | -177.42% | 5,111.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,123,723.43% | -7,432,711.19% | -2,155,867.55% | -4,095.83% | -29,008,488.20% | -13,043,961.64% | -38,838,402.29% | -6,121,142.68% | -2,948.96% | 0.00% | 0.00% | -3,142.69% | -903,604,900.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.19M | 20.43M | 39.03M | -74.49M | -902.04K | 2.04M | 4.72M | -1.89M | 1.72M | 3.27M | 4.54M | 20.44M | 330.60K | 40.31K | -12.44M | -1.17M | 69.97K | 115.17K | 16.00K | 10.66K | 7.91K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -33.34M | -9.34M | 36.33M | -70.02M | -3.22M | -2.19M | -1.42K | -8.55M | -9.49M | -21.68M | -25.28M | -45.81M | -36.23M | -23.50M | -67.97M | -24.00M | -18.36M | -13.26M | -13.69M | -27.10M | -8.84M | -6.24M | -4.66M | -1.36M | -360.00K |
| Net Income Ratio | -1,252.54% | -150.58% | 5,166.64% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -33,123.72% | -7,432.71% | -2,155.87% | -4,095.83% | -29,008.49% | -13,043.96% | -38,838.40% | -6,121.14% | -2,927.78% | 0.00% | 0.00% | -2,709.72% | -884,104,700.00% | -623,960,200.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.46 | -0.14 | 0.48 | -2.41 | -0.12 | -0.09 | 0.00 | -0.66 | -0.97 | -2.59 | -3.43 | -10.79 | -11.10 | -7.37 | -30.65 | -22.34 | -20.70 | -21.60 | -22.54 | -49.11 | -19.80 | -16.01 | -15.74 | -4.25 | -7.20 |
| EPS Diluted | -0.46 | -0.14 | 0.48 | -2.41 | -0.12 | -0.09 | 0.00 | -0.66 | -0.97 | -2.59 | -3.43 | -10.79 | -11.10 | -7.37 | -30.65 | -22.34 | -20.70 | -21.60 | -22.54 | -49.11 | -19.80 | -16.01 | -15.74 | -4.25 | -7.20 |
| Weighted Avg Shares Out | 73.11M | 67.70M | 76.18M | 29.03M | 25.90M | 23.32M | 19.98M | 13.04M | 9.77M | 8.37M | 7.38M | 4.25M | 3.26M | 3.19M | 2.22M | 1.07M | 886.93K | 614.02K | 607.41K | 551.81K | 446.58K | 389.85K | 296.32K | 320.00K | 50.00K |
| Weighted Avg Shares Out (Dil) | 73.11M | 67.70M | 76.18M | 29.03M | 25.90M | 23.32M | 19.98M | 13.04M | 9.77M | 8.37M | 7.38M | 4.25M | 3.26M | 3.19M | 2.22M | 1.07M | 886.93K | 614.02K | 607.41K | 551.81K | 446.58K | 389.85K | 296.32K | 320.00K | 50.00K |
Source: https://incomestatements.info
Category: Stock Reports